THTX — Theratechnologies Income Statement
0.000.00%
Last trade - 00:00- $147.42m
- $181.12m
- $85.87m
- 39
- 71
- 77
- 67
Annual income statement for Theratechnologies, fiscal year end - November 30th, USD millions except per share, conversion factor applied.
2020 November 30th | 2021 November 30th | 2022 November 30th | 2023 November 30th | 2024 November 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 66.1 | 69.8 | 80.1 | 81.8 | 85.9 |
| Cost of Revenue | |||||
| Gross Profit | 38.2 | 46.6 | 53.8 | 62.1 | 65.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 84 | 95.1 | 120 | 95.8 | 83.6 |
| Operating Profit | -18 | -25.2 | -39.6 | -14 | 2.28 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22.7 | -31.7 | -46.8 | -23.5 | -6.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -22.7 | -31.7 | -47.2 | -24 | -8.31 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.7 | -31.7 | -47.2 | -24 | -8.31 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -22.7 | -31.7 | -47.2 | -24 | -8.31 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.21 | -1.37 | -1.99 | -0.825 | -0.038 |